Name,Category,Begin Date,End Date,Note
Severe Jaundice and Pruritis,Milestones,2022-12-01,,Rapidly progressive symptoms
Emergency ERCP,Milestones,2022-12-03,,Biliary decompression
CT Scan,Biomarker Assess,2022-12-05,,Large perihilar mass with liver mets
Liver Biopsy,Biomarker Assess,2022-12-08,,Poorly differentiated CCA
CA 19-9,Biomarker Assess,2022-12-10,,5400 U/mL very high
Stage IV Diagnosis,Milestones,2022-12-12,,Extensive disease at presentation
Molecular Testing,Biomarker Assess,2022-12-15,,No actionable targets MSS
GemCis Started Urgently,Line 1 treatment,2022-12-20,2023-03-28,Started quickly due to symptoms
6-Week Restaging,Biomarker Assess,2023-02-01,,Mixed response
CA 19-9 Rising,Biomarker Assess,2023-02-01,,Up to 6800 U/mL
Biliary Sepsis,Complications,2023-02-15,,Hospitalized stent revision
GemCis Resumed,Line 1 treatment,2023-03-01,2023-03-28,Completing planned cycles
Progression on GemCis,Complications,2023-04-05,,Liver mets growing
FOLFOX 2L,Line 2 treatment,2023-04-17,2023-08-14,Second-line per ABC-06
Brief Stabilization,Biomarker Assess,2023-06-17,,Transient stable disease
FOLFOX Progression,Complications,2023-08-20,,New peritoneal disease
Gemcitabine/Abraxane 3L,Line 3 treatment,2023-09-05,2023-12-05,Off-label combination
Declining Performance,Complications,2023-11-15,,ECOG 2 worsening
Goals of Care Discussion,Milestones,2023-12-10,,Transition to comfort focus
Hospice Enrollment,Milestones,2023-12-20,,Home hospice initiated
